COVID-19: Research Luxembourg is mobilising
27 March 2020
Research Luxembourg, a joint initiative of the main players in Luxembourg’s public research sector, is mobilising its knowledge and its human and material resources to help address the challenge of COVID-19. A task force has been set up in order to offer the health system the combined expertise available within the Luxembourg public research sector (LIH, LISER, LIST, LNS, University, FNR, under the coordination of the Ministry of Higher Education and Research).
The missions of this working group are:
- Coordinate the provision of support from the national research community to healthcare providers and the government in order to contain the current COVID-19 pandemic.
- Help identify and centralise a variety of priority activities, leveraging on the cross-sectoral expertise in molecular biology, epidemiology, clinical trials and fundamental research
- Be the point of contact between the national research ecosystem, the clinical community and the authorities
The task force will focus on three pillars:
– a prevalence study to assess the extent of the spread of the virus and the number of asymptomatic individuals;
– a stratification study in which researchers attempt to identify risk factors that contribute negatively to disease progression;
– statistical simulations on the evolution, impact and spread of the COVID-19 pandemic to provide short- and medium-term projections and thus facilitate decision-making on when restrictions could be lifted.
Concrete actions have already been put in place. Research institutions have provided the health sector with equipment and specialised personnel. In this context, it is worthwhile mentioning the important mobilisation of doctors in training in the framework of the “formation spécifique en médecine générale”. Indeed, many of these future general practitioners have volunteered to support hospital staff in the four hospital establishments in Luxembourg.
To enable this initiative, the government, with the support of the University of Luxembourg and the doctors involved in this training, has adjusted the relevant regulatory framework and adopted the necessary measures to enable the deployment of these volunteers in the coming days. Likewise, nurses working in research as well as students in medicine are also being trained to support hospital staff.
Due to the international pressure exerted by governments and research funding agencies, almost all scientific data and publications on COVID-19 are freely accessible in digital form (machine readable). This data is a very valuable resource, easily amenable to text and data mining using artificial intelligence techniques. This is an area in which Luxembourg has strong expertise.
To accelerate these efforts and to stimulate new ideas and new collaborations between researchers, additional funding will be provided by the Luxembourg National Research Fund (FNR). Given the urgency of the situation, quick funding decisions will be ensured.
Luxembourg: a model student in parental leaveThe arrival of a child is one of the most important moments in one’s life, and adjusting to the arrival…
Physical activity to reduce the severity of COVID-19A consortium of Luxembourgish research institutions studying the national population have been looking to identify factors that may contribute to…
Superimmunity: A defence mechanism against COVID-19?Two years after the pandemic outbreak, researchers and scientists continue to look at the immune system’s defence mechanisms against the…
The why behind mild COVID-19From the start of the COVID-19 pandemic, the majority of published studies have focused on severe COVID-19 patients in order…
In conversation with our young researchers: Abir ElbéjiHow to better follow COVID-19-related symptoms thanks to new digital biomarkers and tools and how to improve Long Covid patients’…
Shedding light on COVID-19 – Presentation of CoVaLuxDespite the worldwide COVID-19 pandemic entering its third year, open questions pertaining to the occurrence of new variants, ensuing new…
Europe must come together to confront OmicronOmicron. The SARS-CoV-2 Omicron variant is spreading rapidly in Europe, even in countries with high levels of vaccination, including those…
What are the benefits, costs and feasibility of a low incidence COVID-19 strategyA low incidence strategy. Lifting some non-pharmaceutical interventions means living with a relatively high incidence of cases. Such a high…